Results for "antiviral"
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
First published: 16 August 2016
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
First published: 23 February 2016
32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
First published: 11 July 2012
Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment...
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
First published: 07 November 2011
Full results from ENABLE 1 and initial data from ENABLE 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases
ViiV Healthcare gains CHMP positive opinion for Juluca (dolutegravir/rilpivirine) in Europe
First published: 23 March 2018
ViiV Healthcare today announced that the European Committee for Medicinal Products for Human Use has issued a Positive Opinion recommending marketing authorisation for Juluca.
GSK presents promising phase 2a data for chronic hepatitis B treatment
First published: 28 August 2020
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available
First published: 11 December 2020
Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
First published: 27 October 2017
ViiV Healthcare, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection.
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
First published: 31 October 2018
BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV, including those heavily-treated and failing on current antiretroviral regimens
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
First published: 10 January 2020
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.